Liquid Biopsy to Accelerate Patient Enrollment in Clinical Trials

Predicine is an international precision medicine organization committed to accelerating clinical trials worldwide. With CLIA- and CAP-standard facilities in the U.S. and China, Predicine provides an integrated biomarker solution that includes an innovative RNA+DNA liquid biopsy test, a one-stop biomarker and data analysis platform, and patient pre-screening program to accelerate patient enrollment in clinical trials. Its business spans the globe to support biomarker-driven clinical trials in China, the U.S., and worldwide.

Dr. Shidong Jia, Founder and CEO, provided insight into Predicine’s liquid biopsy approach to support clinical trials.

Q: How does Predicine accelerate patient enrollment in clinical trials?
A: Patient enrollment is one of the key limiting factors in clinical trials. To improve the efficiency of patient enrollment, Predicine has established a liquid biopsy-based, patient screening and referral program. Today, we are introducing ‘Predi-Trial’, an umbrella patient screening program that provides blood-based, comprehensive genetic testing to advanced cancer patients at our network cancer centers and hospitals.

By detecting genetic alterations using peripheral blood, Predicine classifies cancer patients into different molecular subgroups, and refers patients to matched biomarker-driven clinical trials. We aim to test 100,000 cancer patients in 10 major indications with the goal to accelerate patient enrollment in global clinical trials.

Q: What has prepared Predicine to lead this ambitious initiative?
A: Three differentiating factors: technology innovation, global operations, biomarker and clinical trial expertise. First, Predicine has developed an innovative liquid biopsy test using its proprietary Gene RADAR technology, detecting RNA- and DNA-based genetic alterations using a single tube of blood. Second, Predicine offers a first-in-class, liquid biopsy-based, umbrella patient screening and referral program through its integrated biomarker and data analysis platform in the U.S. and China. Third, Predicine team is composed by a group of industry veterans from Genentech, Novartis, and Roche among others, with extensive biomarker experience in clinical trials. Our mission is to empower the global healthcare ecosystem through innovation.

Q: Why is Predicine’s China operation critical for global drug development?
A: China is being prioritized in global early-phase clinical trials. Recently, the China Food and Drug Administration (CFDA) released new regulatory approval policies that require the inclusion of China sites during the global drug development process. International firms with innovative products are now required to file new drug application (NDA) in China before having NDA approvals outside of China. We recognize this changing landscape in multi-regional clinical trials (MRCT), and have established cross-border operations in California and Shanghai to support global drug development.

Q: Please tell us more about the company’s pipeline?
A: Along with “Predi-Trial” program, we have introduced the Predi-Seq liquid biopsy NGS assay at the recent AACR conference to support investigative drugs in clinical trials for Cancer Immunotherapy, DNA Damage Repair, and Prostate Cancer, among others. In addition, we developed Predi-Act and Predi-Screen liquid biopsy assays for targeted therapy and early cancer detection.

Q: How can our readers find out more about Predicine?
A: For more information, readers can contact us by contact@predicine.com, 877-752-3958 (toll free), visit www.predicine.com (U.S.) and www.predicine.cn (China), or stop by our booth at ASCO #23120.